Skip to main content
Medicure Inc logo

Medicure Inc — Investor Relations & Filings

Ticker · MPH ISIN · CA58469E4085 LEI · 9845007T999BF377B627 TSXV Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2021-05-10 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV MPH

About Medicure Inc

https://www.medicure.com/

Medicure Inc. is a value-based pharmaceutical company specializing in the research, clinical development, and commercialization of human therapeutics. The company is primarily focused on developing and commercializing innovative and affordable medicines within the cardiovascular therapeutic area. Medicure's core mission is to serve patients by delivering safe and efficacious life-changing medicines, with a strategic focus on the U.S. market. It aims to offer a growing portfolio of products and services, ensuring patient access to necessary care.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Medicure Inc. for the three months ended March 31, 2021. It contains detailed unaudited financial statements including statements of financial position, net loss and comprehensive income, changes in equity, and cash flows. The notes indicate compliance with IAS 34 Interim Financial Reporting and mention that these are interim financial statements prepared in accordance with IFRS. The document length is substantial (15,000 characters) and contains actual financial data and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-05-10 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO of Medicure Inc. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2021. It is titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE' and explicitly states it is a certification of interim filings, not the filings themselves. The document is short (3000 characters) and contains no actual financial data or analysis, only the CEO's attestation. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). Therefore, the correct classification is Regulatory Filings (RNS).
2021-05-10 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2021. The document is a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certification and notes differences from non-venture issuer certifications. According to the Certification Rule, documents that are primarily officer certifications, even if referencing interim reports, should be classified as Regulatory Filings (RNS). The document length is short (2985 characters), and it is clearly a certification, not the interim report itself.
2021-05-10 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report from Medicure Inc. reporting financial results for the quarter ended March 31, 2021. It includes comprehensive financial data such as revenue, net loss, EBITDA, cash flows, and balance sheet items, all for a quarterly period. The presence of condensed consolidated interim financial statements (statements of financial position, net loss and comprehensive income, and cash flows) confirms this is a substantive financial report for a period shorter than a full fiscal year. The document also includes management commentary on the results and operational highlights. It is not merely an announcement or a brief summary but contains actual financial statements and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-05-10 English
News release - English.pdf
Earnings Release Classification · 90% confidence The document is a press release announcing the upcoming release of Medicure's 2020 annual and Q1 2021 quarterly financial results, along with details about a conference call to discuss these results. It does not contain the actual financial statements or detailed financial data but rather informs investors about the timing of the report release and the conference call. The document length is 3376 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document is an announcement of a report and conference call, not the report itself. The appropriate classification is 'Call Transcript' (CT) because it announces a conference call related to financial results, but since the transcript itself is not included, and the main focus is on announcing the call and results release, the best fit is 'Call Transcript' as it relates to the earnings call event. However, since the actual transcript is not included and this is primarily an announcement of the call and results release, the more precise classification is 'Earnings Release' (ER) as it announces quarterly and annual financial results and the related call. Given the content, 'Earnings Release' is the best fit. Q1 2021
2021-05-05 English
News release - English.pdf
Regulatory Filings
2021-04-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.